Evidence map›Paper›PMID 38305025›Full record

ArticleGlobal health action2024

Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho.

Lawrence Oyewusi, Chengbo Zeng, K J Seung, Stephanie Mpinda, Mikanda Kunda, Carole D Mitnick, Makelele Kanu, Meseret Tamirat, Joalane Makaka, Mabatloung Mofolo and 6 more

Abstract read
In one paragraph

Article in Global health action, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lawrence OyewusiClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Chengbo ZengDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
K J SeungDivision of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.
Stephanie MpindaClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Mikanda KundaClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Carole D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Makelele KanuClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Meseret TamiratClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Joalane MakakaClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Mabatloung MofoloClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Refiloe MaimeClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Llang MaamaNational TB and Leprosy Programme, Lesotho Ministry of Health, Maseru, Lesotho.
Ninza SenyoClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Bamidele OguntoyinboClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Lwayi MayomboClinical department (MDRTB), Partners In Health, Maseru, Lesotho.
Molly F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA low body mass index (BMI) at the start of treatment for rifampicin- or multidrug-resistant tuberculosis (MDR/RR-TB) is associated with poor treatment outcomes and may contribute to delayed sputum culture conversion, thereby prolonging the period of potential transmission to others. Whether the relative importance of low BMI in predicting treatment outcomes differs by HIV status is unclear.

objectivesWe evaluated the association between low BMI and two dependent variables, sputum culture conversion and end-of-treatment outcome, among patients receiving treatment for MDR/RR-TB in Lesotho, a setting with a high prevalence of HIV infection.

methodsSecondary data from a prospective cohort of patients initiating a longer (18-20 months) treatment containing bedaquiline and/or delamanid under routine programmatic conditions in Lesotho were analysed. Risk ratios and differences were adjusted for potential confounders using multivariable logistic regression, and estimates were stratified by HIV status.

resultsOf 264 patients, 105 and 250 were eligible for culture conversion and end-of-treatment analyses, respectively. Seventy-one per cent of patients (74/105) experienced culture conversion within six months, while 74% (184/250) experienced a favourable end-of-treatment outcome. Low BMI was associated with a lower frequency of culture conversion at six months among those who were not living with HIV (relative risk [RR]: 0.50 [95% CI: 0.21, 0.79]); this association was attenuated among those living with HIV (RR: 0.88 [95% CI: 0.68, 1.23]). A low BMI was moderately associated with a lower frequency of treatment success (RR = 0.89 [95% CI: 0.77, 1.03]), regardless of HIV status.

conclusionsLow BMI was common and associated with the frequency of six-month culture conversion and end-of-treatment outcomes. The association with culture conversion was more pronounced among those not living with HIV. Addressing the myriad factors that drive low BMI in this setting could hasten culture conversion and improve end-of-treatment outcomes. This will require a multipronged approach focused on alleviating food insecurity and enabling prompt diagnosis and treatment of HIV and TB.

Indexed as

HIV InfectionsTuberculosis, Multidrug-ResistantAntitubercular AgentsBody Mass IndexHumansLesothoProspective StudiesSputumTreatment OutcomeAntitubercular AgentsBMIculture conversionLesothoMDRTBnew drugs

Identifiers

PMID38305025
PMCPMC10840591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.